Loading clinical trials...

Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients

NCT01755078•Chugai Pharma Taiwan

View on ClinicalTrials.gov

Summary

The study is designed to compare sevelamer vs. calcium-based phosphate binder in hemodialysis patients to achieve full-scale of medical care, including reduction of atherosclerotic risk factors, reduction of vascular access reconstruction rate, and pharmacoeconomic analysis.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Males or females aged between 18-70 years old
•Subject with hyperphosphatemia (5.5 - 8.5 mg/dL) at both WK(-2) and WK0
•On stable TIW hemodialysis for 3 months or longer

Exclusion Criteria

•Patients with hypercalcemia (corrected serum calcium \> 10.5 mg/dL)
•Any of the following abnormalities: ALT or AST \> 3X ULN; iPTH \> 1000 or \< 150 pg/mL
•History of dysphagia or swallowing disorders
•History of GI motility disorder or GI bleeding within 3 months prior to entry

Key Dates

Start Date

June 1, 2007

Primary Completion Date

June 1, 2009

Completion Date

June 1, 2009

Last Updated

August 5, 2014

Enrollment

166

ACTUAL participants

Conditions

HemodialysisHyperphosphatemiaCardiovascular Events

Interventions

Sevelamer HCl

DRUG

Calcium-based phosphate binder

DRUG

The Effectiveness of Education in Diabetic Hemodialysis Patients

NCT07462741

Hemodialysis PatientDiabetes Foot Care

View study

RECRUITINGPHASE3

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

NCT06933472

HyperphosphatemiaChronic Kidney Disease, Receiving Dialysis+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 5, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients

Inclusion Criteria

Exclusion Criteria

The Effectiveness of Education in Diabetic Hemodialysis Patients

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Using a Hypotension Prediction Index to Prevent Low Blood Pressure During Dialysis in ICU Patients

Predictive Value of Carotid Ultrasonography for Intradialytic Hypotension

PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI

Effect of a Structured Physical Exercise Program on Arteriovenous Fistula Maturation for Hemodialysis in Chronic Kidney Disease Patients